Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 11/20 | 0.64 |
| ▸ | PDGFRB known ✓ | P09619 | 3/20 | 0.64 |
| ▸ | KDR known ✓ | P35968 | 3/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.64 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.64 |
| ▸ | FYN | P06241 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.64 |
| ▸ | PRKACA | P17612 | 1/20 | 0.54 |
| ▸ | PRKACG | P22612 | 1/20 | 0.54 |
| ▸ | PRKACB | P22694 | 1/20 | 0.54 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686701 | 0.95 | FGFR4 (0.68) | EGFRFGFR4PDGFRBFGFR1PDGFRA | |
| SCHEMBL4692811 | 0.93 | FGFR4 (0.65) | EGFRFGFR4PDGFRBFGFR1PDGFRA | |
| SCHEMBL4689744 | 0.91 | EGFR (0.62) | EGFRFGFR4PDGFRBFGFR1PDGFRA | |
| SCHEMBL4689940 | 0.85 | EGFR (0.56) | EGFRFGFR4PDGFRBFGFR1PDGFRA | |
| SCHEMBL5769182 | 0.85 | FGFR4 (0.85) | EGFRFGFR4PDGFRBFGFR1PDGFRA | |
| SCHEMBL5831732 | 0.82 | FGFR4 (0.64) | EGFRFGFR4PDGFRBFGFR1PDGFRA | |
| SCHEMBL5770266 | 0.80 | FGFR4 (0.65) | EGFRFGFR4PDGFRBFGFR1PDGFRA | |
| SCHEMBL5747471 | 0.80 | FGFR4 (0.65) | EGFRFGFR4PDGFRBFGFR1PDGFRA | |
| SCHEMBL5768633 | 0.80 | FGFR4 (0.62) | EGFRFGFR4PDGFRBFGFR1PDGFRA | |
| SCHEMBL5771946 | 0.80 | FGFR4 (0.62) | EGFRFGFR4PDGFRBFGFR1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556384-B1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | claimed |
| US-7084270-B2 | Pyrimido compounds having antiproliferative activity | HOFFMAN-LA ROCHE INC. (US) | 2006-08-01 | — | — | US | claimed |
| EP-1556384-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-27 | — | — | EP | claimed |
| WO-2004018472-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-04 | — | — | WO | claimed |
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-02-26 | — | — | US | claimed |
| EP-1556384-B1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-7084270-B2 | Pyrimido compounds having antiproliferative activity | HOFFMAN-LA ROCHE INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1556384-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004018472-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-04 | — | — | WO | disclosed |
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | LCK, FGFR1, FGFR3 | EGFR 45/4885PDGFRB 13/4885KDR 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.